Cobra Signs Agreement with Cequent to Evaluate Cobra's ORT Technology for RNAi Delivery
News Jan 24, 2007
UK based Cobra Biomanufacturing Plc has signed an agreement with Cambridge, MA based Cequent Pharmaceuticals, Inc. to develop a treatment for, an inherited form of bowel tumour, Familial Adenomatous Polyposis (FAP).
The treatment will incorporate Cobra's proprietary antibiotic free maintenance technology (ORT) in conjunction with Cequent's proprietary TransKingdom RNA interference (tkRNAi) technology.
Commenting on the contract, David Thatcher, CEO at Cobra, said: "We are delighted to work with Cequent on this exciting project. Interference RNA (RNAi) has great potential for medicine, and Cequent's tkRNAi technology clearly represents an important breakthrough for the difficult, but exciting field of RNAi delivery. We believe the combination of Cobra's ORT technology with Cequent’s in vivo delivery platform will have significant clinical benefit."
Peter Parker, President and CEO at Cequent, said: "Cobra has an excellent track record of developing innovative solutions for molecular biology and biologic therapy, and we look forward to collaborating with Cobra's outstanding scientific team to evaluate their ORT technology for use in our therapeutic tkRNAi bacteria.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.